PO.IM01.11 · 免疫学

SRY-mediated upregulation of PD-L1 promotes immune evasion in hepatocellular carcinoma and contributes to sex-specific disparities in immunotherapy response

海报缩略图:SRY-mediated upregulation of PD-L1 promotes immune evasion in hepatocellular carcinoma and contributes to sex-specific disparities in immunotherapy response
编号 2801 展板 6 时间 4/20 02:00–05:00 区域 Section 7 主讲 Bingyi Ren, MBBS
分会场 Immune Checkpoints
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Bingyi Ren, Kai Sheng, Yichen Yang

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi‘an’, China

摘要 Abstract

Background: The impact of sex chromosomes on the tumor microenvironment (TME) is significant, beyond hormonal effects. This study investigates the role of the sex-determining gene SRY in the immune microenvironment of hepatocellular carcinoma (HCC), focusing on how SRY regulates immune checkpoints and contributes to gender disparities in immunotherapy response. Methods: Multiple HCC mouse models (chemically induced, hydrodynamic, orthotopic, subcutaneous) using SRY transgenic knockout (KO) or knock-in (KI) mice were employed. To eliminate hormonal effects, the mice were castrated. Flow cytometry, immunofluorescence, and ELISA assessed T cell changes in the TME. Cellular models used PCR array, CUT&Tag, qPCR, WB, and luciferase assays to explore SRY's transcriptional regulation. Clinical samples validated correlations between SRY, immune markers, and PD-L1. Results: •In castrated male SRY-KO mice, increased CD8 + T cells and elevated GZMB, TNF-alpha, and IFN-gamma were observed in the TME.•SRY-KI in castrated males reduced CD8 + T cells and functional markers.•Ectopic SRY in castrated females similarly impaired T cell infiltration and function.•PCR array in SRY-overexpressing HCC cells revealed upregulation of PD-L1.•CUT&Tag and luciferase assays confirmed SRY binds the IRF1 promoter, upregulating IRF1 expression.•IRF1 knockdown abolished PD-L1 upregulation, confirming an SRY-IRF1-PD-L1 axis.•In vivo, PD-L1 knockdown in SRY-overexpressing tumors reversed immune suppression and tumor growth.•Anti-PD-L1 treatment showed enhanced efficacy in SRY-overexpressing tumors.•Clinical HCC samples confirmed positive SRY-PD-L1 correlation and negative SRY-CD8 + T cell correlation. Conclusions: SRY, a male-specific gene, regulates the immune checkpoint PD-L1 via IRF1, suppressing CD8 + T cell function in the TME. Targeting the SRY-IRF1-PD-L1 axis may improve immunotherapy outcomes, especially in male HCC patients. The text has been translated and polished using AI.
利益披露 Disclosure
B. Ren, None.. K. Sheng, None.. Y. Yang, None.

在会议检索中打开